allergic conjunctivitis
Information
- Disease name
- allergic conjunctivitis
- Disease ID
- DOID:11204
- Description
- "A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant." [url:http\://en.wikipedia.org/wiki/Allergic_conjunctivitis] {comment="ls:IEDB"}
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05186025 | Active, not recruiting | Tyrosine Allergoid Paediatric and Adult Study | November 6, 2020 | October 2026 | |
| NCT04619017 | Active, not recruiting | Phase 1 | Airway Immune Response to Allergens (Use Lay Language Here) | October 28, 2021 | March 1, 2024 |
| NCT00331500 | Completed | Phase 3 | Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis | April 18, 2006 | July 27, 2006 |
| NCT00364091 | Completed | Phase 3 | Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis | August 2006 | |
| NCT00889330 | Completed | Phase 3 | Safety and Efficacy Study of a Eye Drop for Eye Allergy | April 2009 | |
| NCT00244543 | Completed | Phase 3 | Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis | October 2005 | |
| NCT03231969 | Completed | Phase 2 | A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model | July 20, 2017 | October 11, 2017 |
| NCT03320434 | Completed | Phase 2 | Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis | October 13, 2017 | February 18, 2018 |
| NCT03368339 | Completed | Phase 2 | Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis | December 10, 2017 | January 28, 2018 |
| NCT03479307 | Completed | Phase 3 | A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. | April 7, 2018 | August 10, 2018 |
| NCT03489941 | Completed | Phase 3 | A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle | April 7, 2018 | April 29, 2018 |
| NCT03494504 | Completed | Phase 3 | ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis | March 30, 2018 | November 5, 2018 |
| NCT03660878 | Completed | Phase 1/Phase 2 | A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis | September 8, 2018 | November 19, 2019 |
| NCT03682965 | Completed | Phase 2 | Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study | September 28, 2018 | April 29, 2019 |
| NCT03755557 | Completed | Phase 3 | Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray | November 19, 2018 | April 5, 2019 |
| NCT03861910 | Completed | Dietary Choice for the Management of Cow's Milk Allergy Influences Other Allergic Manifestations | December 2014 | December 2021 | |
| NCT04050865 | Completed | Phase 3 | A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis | August 5, 2019 | February 28, 2020 |
| NCT04207736 | Completed | Phase 3 | The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. | December 5, 2019 | February 16, 2021 |
| NCT04389034 | Completed | Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels | April 22, 2020 | October 5, 2020 | |
| NCT04532710 | Completed | Phase 2 | Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis | August 4, 2020 | May 27, 2021 |
| NCT04622345 | Completed | Phase 2 | Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies | November 21, 2020 | June 28, 2021 |
| NCT04641130 | Completed | N/A | Clinical Validation Study in Allergic Conjunctivitis to Birch Pollen During Allergen Challenge in ALYATEC EEC | July 13, 2017 | September 11, 2017 |
| NCT04776096 | Completed | Phase 4 | Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment | March 10, 2021 | August 18, 2022 |
| NCT04810390 | Completed | Phase 3 | Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children | March 26, 2021 | November 30, 2022 |
| NCT05234554 | Completed | Phase 3 | The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis | January 21, 2022 | April 22, 2023 |
| NCT05265910 | Completed | Phase 4 | A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis | December 14, 2021 | April 23, 2022 |
| NCT05314621 | Completed | Phase 4 | A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis | December 31, 2021 | July 24, 2022 |
| NCT05579730 | Completed | Phase 3 | Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis | November 18, 2022 | July 22, 2023 |
| NCT05815758 | Completed | Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | April 20, 2023 | September 18, 2023 | |
| NCT05824000 | Completed | N/A | PMCF Study to Evaluate Performance and Safety of "Optrex Double Action Soothing and Lubricating Drops" | June 7, 2022 | August 5, 2022 |
| NCT05829499 | Completed | N/A | PMCF Study to Evaluate Performance and Safety of "Xanoftal Next" | December 2, 2022 | February 6, 2023 |
| NCT00389025 | Completed | Phase 4 | Mast-Cell Stabilizing Effects of Olopatadine | October 2006 | |
| NCT00423007 | Completed | Phase 3 | Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis | November 2006 | August 2007 |
| NCT00432757 | Completed | Phase 3 | Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis | January 2007 | March 2007 |
| NCT00445874 | Completed | Phase 3 | Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis | February 2007 | May 2007 |
| NCT00534794 | Completed | Phase 4 | Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis | October 2007 | |
| NCT00559546 | Completed | Phase 4 | Montelukast as a Controller of Atopic Syndrome | March 2007 | July 2007 |
| NCT00569777 | Completed | Phase 3 | Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers | October 2007 | March 2008 |
| NCT00574379 | Completed | Phase 2 | Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR | December 2007 | March 2008 |
| NCT00586625 | Completed | Phase 3 | Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers | October 2007 | |
| NCT00586664 | Completed | Phase 3 | Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis | October 2007 | June 2008 |
| NCT00609128 | Completed | N/A | Effect of Olopatadine on Allergic Tear Mediators | September 2000 | November 2009 |
| NCT00689078 | Completed | Phase 4 | Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model | May 2008 | June 2008 |
| NCT00769886 | Completed | Phase 3 | Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. | October 2008 | June 2009 |
| NCT00770133 | Completed | Phase 3 | Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis. | February 2010 | June 2010 |
| NCT00775658 | Completed | N/A | Olopatadine Eye Drops and Allergy Skin Testing | January 2008 | June 2008 |
| NCT00818805 | Completed | Phase 4 | Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) | July 2008 | |
| NCT00833495 | Completed | Phase 2 | Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation | January 2009 | March 2009 |
| NCT00836485 | Completed | Phase 2 | Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis | February 2009 | March 2009 |
| NCT00882687 | Completed | Phase 2 | Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis | April 24, 2009 | May 10, 2009 |
| NCT00889252 | Completed | Phase 3 | Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers | April 2009 | |
| NCT00241319 | Completed | Phase 3 | Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis | October 2005 | |
| NCT00982163 | Completed | A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season | August 2008 | September 2009 | |
| NCT00987272 | Completed | Phase 3 | Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects | October 2009 | November 2009 |
| NCT01001091 | Completed | Phase 2 | AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation | December 2009 | April 2010 |
| NCT01037179 | Completed | Phase 3 | An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis | February 2010 | May 2010 |
| NCT01107405 | Completed | Phase 2 | Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge | April 2010 | August 2010 |
| NCT01109485 | Completed | Phase 4 | Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients | March 2010 | July 2011 |
| NCT01119287 | Completed | Phase 4 | Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis | March 2010 | September 2010 |
| NCT01120132 | Completed | Phase 2 | Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis | May 2010 | August 2010 |
| NCT01134328 | Completed | Phase 2 | Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model | May 2010 | July 2010 |
| NCT01159015 | Completed | Phase 3 | Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers | July 2010 | October 2010 |
| NCT01159769 | Completed | Phase 4 | Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis | June 2010 | August 2010 |
| NCT01174823 | Completed | Phase 2 | Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients | June 2010 | December 2010 |
| NCT01203540 | Completed | Phase 4 | Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients | October 2010 | January 2011 |
| NCT01272089 | Completed | Phase 4 | A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis | May 2011 | December 2011 |
| NCT01275105 | Completed | Phase 2 | A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC) | January 2011 | March 2011 |
| NCT01282138 | Completed | Phase 4 | Assessment of Alcon's Ocular Image Quantification System | December 2010 | March 2011 |
| NCT01294969 | Completed | Phase 4 | Patient Perception Study for AL-4943A | September 2010 | October 2011 |
| NCT01320553 | Completed | Phase 2 | Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis | June 2011 | September 2011 |
| NCT01326858 | Completed | Phase 1 | Safety and Comfort of AL-4943A Ophthalmic Solution | April 2011 | June 2011 |
| NCT01332188 | Completed | Phase 2/Phase 3 | Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model | April 2011 | October 2011 |
| NCT01339507 | Completed | A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft | April 2011 | June 2011 | |
| NCT01346371 | Completed | Phase 4 | The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer | May 2011 | September 2012 |
| NCT01363700 | Completed | Phase 3 | Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis | ||
| NCT01363713 | Completed | Phase 3 | A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis | ||
| NCT01439815 | Completed | Phase 4 | An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo | September 2011 | October 2011 |
| NCT01443442 | Completed | Phase 4 | Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis | October 2011 | December 2012 |
| NCT01471184 | Completed | Phase 1 | The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo | September 2009 | |
| NCT01479374 | Completed | Phase 3 | Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model | January 2012 | March 2012 |
| NCT01534195 | Completed | Phase 4 | Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model | January 2012 | February 2012 |
| NCT01551056 | Completed | Phase 3 | A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) | March 2012 | June 2012 |
| NCT01561521 | Completed | Phase 3 | An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis | March 2012 | April 2012 |
| NCT01639846 | Completed | Phase 2 | Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis | July 2012 | August 2012 |
| NCT01679015 | Completed | Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes | August 2012 | February 2014 | |
| NCT01685242 | Completed | Phase 3 | A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle | September 2012 | November 2012 |
| NCT01686048 | Completed | The Significance of Ambrosia in Allergic Rhinitis and Asthma in Israel | April 2015 | April 2015 | |
| NCT01697969 | Completed | Phase 4 | Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients | September 2012 | July 2013 |
| NCT01698814 | Completed | Phase 3 | A Six-Week Safety Study of an Investigational Ophthalmic Solution | October 2012 | January 2013 |
| NCT01731249 | Completed | Phase 3 | Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis | November 2010 | October 2012 |
| NCT01743027 | Completed | Phase 3 | Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis | January 2013 | July 2013 |
| NCT01754766 | Completed | Phase 2 | AGN-229666 for the Treatment of Allergic Conjunctivitis | October 2012 | February 2013 |
| NCT01881113 | Completed | Phase 3 | A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle | June 2013 | October 2013 |
| NCT02079649 | Completed | Phase 2 | Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis | April 2014 | July 2014 |
| NCT02082899 | Completed | Phase 2 | A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1) | February 2014 | July 2014 |
| NCT02148744 | Completed | Phase 1 | Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis | May 2014 | September 21, 2015 |
| NCT02251613 | Completed | Phase 4 | Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan | December 2013 | January 2014 |
| NCT02308501 | Completed | Phase 4 | A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy | December 2014 | February 2015 |
| NCT02322216 | Completed | Phase 3 | Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects | December 2014 | October 2015 |
| NCT02578914 | Completed | Phase 2 | A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis | August 2015 | December 2015 |
| NCT02978183 | Completed | Phase 2 | Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis | December 2016 | November 2017 |
| NCT03101618 | Completed | Animal Allergy in Korean Pet Owners, Pet-related Industry Workers, and Laboratory Animal Reseachers | August 24, 2016 | November 27, 2016 | |
| NCT06459219 | Not yet recruiting | Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects | October 1, 2024 | October 1, 2028 | |
| NCT04198740 | Recruiting | Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface | February 1, 2020 | January 2035 | |
| NCT05839938 | Recruiting | N/A | The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis | August 8, 2022 | July 31, 2025 |
| NCT05969236 | Recruiting | Phase 1 | A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults | October 6, 2023 | October 2024 |
| NCT06293820 | Recruiting | Phase 2 | A Study Of TL-925 For The Treatment of AC | March 2024 | May 2024 |
| NCT06153342 | Recruiting | Phase 2 | A Study of TL-925 for the Treatment of Allergic Conjunctivitis | November 2023 | January 2024 |
| NCT03627689 | Terminated | N/A | Molekule for Allergic Rhinitis/Asthma | July 13, 2018 | January 31, 2019 |
| NCT00276445 | Terminated | Phase 4 | Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan | January 2004 | June 2004 |
| NCT01860664 | Terminated | Phase 2 | Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis | May 2013 | January 1, 2017 |
| NCT03038971 | Terminated | Phase 1 | Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections | March 30, 2017 | April 29, 2017 |
| NCT04695795 | Unknown status | Sea Water in Allergic Conjunctivitis | February 1, 2021 | December 1, 2022 | |
| NCT01337557 | Unknown status | Phase 4 | Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses | May 2011 | November 2011 |
| NCT00443105 | Unknown status | Phase 2 | Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study | ||
| NCT01012752 | Unknown status | Phase 3 | A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts | October 2016 | October 2017 |
| NCT01808768 | Unknown status | Phase 4 | Ocular Allergy Treatment Practical Impact Trial | April 2013 | November 2013 |
| NCT01390961 | Unknown status | Phase 4 | Comparison of Tolerability Between Two Allergy Drops | August 2011 | January 2012 |
| NCT01878929 | Unknown status | Phase 1/Phase 2 | The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions | April 2013 | April 2014 |
| NCT00298337 | Unknown status | Phase 2/Phase 3 | Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 | October 1999 | December 2007 |
| NCT03812952 | Unknown status | China Red Eye Study on Allergic Conjunctivitis | August 1, 2018 | December 31, 2019 | |
| NCT03820154 | Unknown status | N/A | Diagnostic Equivalence of the Skin Prick Test Tape vs. Conventional Skin PrickTest | March 1, 2019 | July 30, 2019 |
| NCT03862053 | Withdrawn | Phase 4 | Manuka Eye Droops for Treatment of Allergy | January 1, 2020 | October 7, 2020 |
| NCT00881673 | Withdrawn | Phase 2 | To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge | May 2009 | May 2009 |
| NCT00375596 | Withdrawn | Phase 2 | A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis | ||
| NCT01657240 | Withdrawn | Phase 3 | Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis | November 2014 | May 2015 |
| NCT00489398 | Withdrawn | Phase 4 | Comparison of CL Wear Between Two Allergy Drops | July 2007 | December 2008 |
- Disase is a (Disease Ontology)
- DOID:2475
- Cross Reference ID (Disease Ontology)
- MESH:D003233
- Cross Reference ID (Disease Ontology)
- NCI:C34506
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:231854006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0009766
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0007879